|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMC5 |
Gene summary for TMC5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMC5 | Gene ID | 79838 |
| Gene name | transmembrane channel like 5 | |
| Gene Alias | TMC5 | |
| Cytomap | 16p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q6UXY8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79838 | TMC5 | P75T-E | Human | Esophagus | ESCC | 3.02e-39 | 1.67e+00 | 0.1125 |
| 79838 | TMC5 | P76T-E | Human | Esophagus | ESCC | 3.49e-06 | 3.05e-01 | 0.1207 |
| 79838 | TMC5 | P82T-E | Human | Esophagus | ESCC | 6.51e-23 | 2.32e+00 | 0.1072 |
| 79838 | TMC5 | P84T-E | Human | Esophagus | ESCC | 2.46e-06 | 8.14e-01 | 0.0933 |
| 79838 | TMC5 | P94T-E | Human | Esophagus | ESCC | 3.00e-14 | 1.96e+00 | 0.0879 |
| 79838 | TMC5 | P104T-E | Human | Esophagus | ESCC | 4.51e-28 | 2.10e+00 | 0.0931 |
| 79838 | TMC5 | P126T-E | Human | Esophagus | ESCC | 3.58e-02 | 9.01e-01 | 0.1125 |
| 79838 | TMC5 | P127T-E | Human | Esophagus | ESCC | 6.49e-16 | 8.02e-01 | 0.0826 |
| 79838 | TMC5 | P128T-E | Human | Esophagus | ESCC | 3.81e-11 | 8.87e-01 | 0.1241 |
| 79838 | TMC5 | HCC1_Meng | Human | Liver | HCC | 2.52e-12 | 2.01e-02 | 0.0246 |
| 79838 | TMC5 | HCC2_Meng | Human | Liver | HCC | 2.24e-118 | 1.16e+00 | 0.0107 |
| 79838 | TMC5 | HCC2 | Human | Liver | HCC | 3.71e-08 | 2.26e+00 | 0.5341 |
| 79838 | TMC5 | HCC5 | Human | Liver | HCC | 5.06e-03 | 3.77e-01 | 0.4932 |
| 79838 | TMC5 | S027 | Human | Liver | HCC | 6.68e-13 | 7.91e-01 | 0.2446 |
| 79838 | TMC5 | S028 | Human | Liver | HCC | 6.56e-05 | 3.96e-01 | 0.2503 |
| 79838 | TMC5 | S029 | Human | Liver | HCC | 3.88e-12 | 4.58e-01 | 0.2581 |
| 79838 | TMC5 | RNA-P10T2-P10T2-1 | Human | Lung | AAH | 1.62e-07 | 1.08e+00 | -0.1271 |
| 79838 | TMC5 | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 1.52e-07 | 1.09e+00 | -0.1406 |
| 79838 | TMC5 | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 2.47e-02 | 6.53e-01 | -0.1408 |
| 79838 | TMC5 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 3.17e-04 | 8.20e-01 | -0.138 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMC5 | SNV | Missense_Mutation | c.809N>T | p.Ser270Leu | p.S270L | Q6UXY8 | protein_coding | tolerated(0.08) | benign(0.366) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TMC5 | SNV | Missense_Mutation | c.2405N>A | p.Met802Lys | p.M802K | Q6UXY8 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMC5 | SNV | Missense_Mutation | rs766446786 | c.1553G>A | p.Ser518Asn | p.S518N | Q6UXY8 | protein_coding | tolerated(0.57) | benign(0.012) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMC5 | SNV | Missense_Mutation | c.2230N>A | p.Ser744Thr | p.S744T | Q6UXY8 | protein_coding | tolerated(0.45) | benign(0.288) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
| TMC5 | SNV | Missense_Mutation | c.142N>G | p.Pro48Ala | p.P48A | Q6UXY8 | protein_coding | deleterious_low_confidence(0.02) | benign(0.037) | TCGA-B6-A0RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| TMC5 | SNV | Missense_Mutation | c.1882N>A | p.Gly628Arg | p.G628R | Q6UXY8 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| TMC5 | SNV | Missense_Mutation | c.1613C>G | p.Thr538Ser | p.T538S | Q6UXY8 | protein_coding | deleterious(0.03) | benign(0.035) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD | |
| TMC5 | SNV | Missense_Mutation | c.1198N>T | p.Leu400Phe | p.L400F | Q6UXY8 | protein_coding | tolerated(0.33) | benign(0.006) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| TMC5 | insertion | Nonsense_Mutation | novel | c.45_46insCAAATGCAGGTCTTGGCTTTGTGTGCATGACCCAAGATGG | p.Tyr16GlnfsTer10 | p.Y16Qfs*10 | Q6UXY8 | protein_coding | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| TMC5 | insertion | Frame_Shift_Ins | novel | c.86_87insCCAAATGCAGGTC | p.Leu30GlnfsTer51 | p.L30Qfs*51 | Q6UXY8 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |